SUCLG2 and prostate carcinoma: In prostate cancer, leukemia inhibitory factor receptor (LIFR) was found to upregulate the mRNA expression of SUCLG2 by activating signal transducer and activator of transcription 3 (STAT3), thus promoting the proliferation of prostate cancer cells and neuroendocrine differentiation (NE).[3] The SUCLG2 sequence is highly conserved.